{"@id":"https://bioecon.ru/technology/peptide-drug-conjugates-via-cspg4/","@type":"Technology","cluster":"therapeutics-platforms","formats":{"html":"https://cn.bioecon.ru/technology/peptide-drug-conjugates-via-cspg4/","json":"https://cn.bioecon.ru/api/v1/technology/peptide-drug-conjugates-via-cspg4/index.json"},"id":"peptide-drug-conjugates-via-cspg4","industries":["pharma","biomanufacturing"],"lang":"cn","links":{"industries":["https://bioecon.ru/industries/pharma/","https://bioecon.ru/industries/biomanufacturing/"],"suppliers":["https://bioecon.ru/companies/genscript-probio-genscript/","https://bioecon.ru/companies/jiangsu-hengrui-medicine/","https://bioecon.ru/companies/daiichi-sankyo/","https://bioecon.ru/companies/lonza-group/","https://bioecon.ru/companies/novartis/","https://bioecon.ru/companies/a-costantino-c-spa/","https://bioecon.ru/companies/isomerase/","https://bioecon.ru/companies/21st-bio/","https://bioecon.ru/companies/isomorphic-labs/"]},"maturity":6,"name":"基于CSPG4靶向受体内吞的多肽偶联药物","regions":["ch","eu","us","cn"],"risk":"medium","section":"technology","sector":"health-biomedicine","sources":[{"date":"2026-11-22","entity":"Swiss Biotech Directory 2026","kind":"vendor","urls":["https://www.swissbiotech.org/directory/"]}],"stages":[{"n":1,"title":"高亲和双环多肽分子设计"},{"n":2,"title":"组织蛋白酶裂解连接子偶联"},{"n":3,"title":"受体介导快速溶酶体内吞"},{"n":4,"title":"双重杀伤与血管正常化"}],"summary":"特异性靶向硫酸软骨素蛋白聚糖4 (CSPG4) 的环肽偶联药物系统，通过受体介导的快速内吞机制将高毒性载荷递送至黑色素瘤与三阴性乳腺癌细胞内部。","url":"/technology/peptide-drug-conjugates-via-cspg4/","verified":"2026-11-22"}